Neuro-focused Lundbeck divests US product portfolio to Recordati for $100m
This article was originally published in Scrip
Italian firm Recordati has acquired a portfolio of products for the treatment of rare and other diseases from H Lundbeck for $100 million, all of which are marketed mainly in the US. The products gave Lundbeck 2011 revenues of $45 million, and are expected to bring in 2013 revenues of around $40 million.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.